NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 1,410 taking part
- Started
- 28 Feb 2020
- Primary completion
- 30 Nov 2025
- Arms
- Phase I: Dose Escalation, Phase II: Triple Negative Breast Cancer, Phase II: Epithelial Ovarian Cancer, Phase II: Non-Small Cell Lung Cancer, Phase II: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Phase II: Extensive-stage Small Cell Lung Cancer, Phase II: HR+/ HER2- Breast Cancer, Phase II: Head and Neck Squamous Cell Carcinoma, Phase II: Endometrial carcinoma, Phase II: Urothelial carcinoma, Phase II: Cervical Cancer
- Results
- None posted
- 5 Nov 2019: Trial registered
- 28 Feb 2020: Trial started